Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents
- PMID: 28279314
- DOI: 10.1016/j.jcin.2016.12.002
Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents
Abstract
Objectives: The authors sought to perform a meta-analysis of randomized clinical trials (RCTs) comparing the safety and efficacy of biodegradable polymer drug-eluting stents (BP-DES) to second-generation durable polymer drug-eluting stents (DP-DES).
Background: Prior meta-analyses have established the superiority of BP-DES over bare-metal stents and first-generation DP-DES; however, their advantage compared with second-generation DP-DES remains controversial.
Methods: The authors searched PubMed and Scopus databases for RCTs comparing BP-DES to the second-generation DP-DES. Outcomes included target vessel revascularization (TVR) as efficacy outcome and cardiac death, myocardial infarction (MI), and definite or probable stent thrombosis (ST) as safety outcomes. In addition, we performed landmark analysis for endpoints beyond 1 year of follow-up and a subgroup analysis based on the stent characteristics.
Results: The authors included 16 RCTs comprising 19,886 patients in the meta-analysis. At the longest available follow-up (mean duration 26 months), we observed no significant differences in TVR (p = 0.62), cardiac death (p = 0.46), MI (p = 0.98), or ST (risk ratio: 0.83, 95% confidence interval: 0.64 to 1.09; p = 0.19). Our landmark analysis showed that BP-DES were not associated with a reduction in the risk of very late ST (risk ratio: 0.87, 95% confidence interval: 0.49 to 1.53; p = 0.62). Similar outcomes were seen regardless of the eluting drug (biolimus vs. sirolimus), the stent platform (stainless steel vs. alloy), the kinetics of polymer degradation or drug release (<6 months vs. >6 months), the strut thickness of the BP-DES (thin <100 μm vs. thick >100 μm), or the DAPT duration (≥6 months vs. ≥12 months).
Conclusions: BP-DES have similar safety and efficacy profiles to second-generation DP-DES.
Keywords: biodegradable polymer; drug-eluting stent(s); durable polymer; meta-analysis.
Published by Elsevier Inc.
Comment in
-
Biodegradable Polymer Drug-Eluting Stents: Can a Class Effect Be Assumed?JACC Cardiovasc Interv. 2017 Mar 13;10(5):474-476. doi: 10.1016/j.jcin.2017.01.005. JACC Cardiovasc Interv. 2017. PMID: 28279315 No abstract available.
Similar articles
-
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011. JACC Cardiovasc Interv. 2013. PMID: 23968698 Clinical Trial.
-
Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials.Cardiovasc Drugs Ther. 2019 Oct;33(5):557-566. doi: 10.1007/s10557-019-06912-x. Cardiovasc Drugs Ther. 2019. PMID: 31773343 Review.
-
Meta-analysis of bioabsorbable versus durable polymer drug-eluting stents in 20,005 patients with coronary artery disease: an update.Catheter Cardiovasc Interv. 2014 May 1;83(6):E193-206. doi: 10.1002/ccd.25416. Epub 2014 Feb 10. Catheter Cardiovasc Interv. 2014. PMID: 24478247 Review.
-
Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.JACC Cardiovasc Interv. 2017 Feb 13;10(3):255-264. doi: 10.1016/j.jcin.2016.11.007. Epub 2017 Jan 18. JACC Cardiovasc Interv. 2017. PMID: 28109874 Clinical Trial.
-
Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials.BMC Cardiovasc Disord. 2018 Aug 15;18(1):170. doi: 10.1186/s12872-018-0902-5. BMC Cardiovasc Disord. 2018. PMID: 30111289 Free PMC article. Review.
Cited by
-
Neointimal characteristics comparison between biodegradable-polymer and durable-polymer drug-eluting stents: 3-month follow-up optical coherence tomography light property analysis from the RESTORE registry.Int J Cardiovasc Imaging. 2020 Feb;36(2):205-215. doi: 10.1007/s10554-019-01718-2. Epub 2019 Oct 31. Int J Cardiovasc Imaging. 2020. PMID: 31673850
-
Short communication: TNF-α and IGF-1 regulates epigenetic mechanisms of HDAC2 and HDAC10.PLoS One. 2022 Feb 10;17(2):e0263190. doi: 10.1371/journal.pone.0263190. eCollection 2022. PLoS One. 2022. PMID: 35143520 Free PMC article.
-
The Use of Bioactive Polymers for Intervention and Tissue Engineering: The New Frontier for Cardiovascular Therapy.Polymers (Basel). 2021 Jan 30;13(3):446. doi: 10.3390/polym13030446. Polymers (Basel). 2021. PMID: 33573282 Free PMC article. Review.
-
Comparison of Thick Biolimus A9-Eluting Stent and Thin Zotarolimus-Eluting Stent in Multi-Vessel Percutaneous Coronary Intervention.Korean Circ J. 2025 May;55(5):396-407. doi: 10.4070/kcj.2024.0101. Epub 2025 Feb 17. Korean Circ J. 2025. PMID: 40097279 Free PMC article.
-
Contemporary Management of Stent Failure: Part One.Interv Cardiol. 2019 Feb;14(1):10-16. doi: 10.15420/icr.2018.39.1. Interv Cardiol. 2019. PMID: 30858886 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical